Who is suitable for treatment with Elafibranor?

Elafibranor (Elafibranor) is a new type of selective PPARα/delta agonist. It is mainly used to treat metabolism-related diseases, especially patients with non-alcoholic steatohepatitis (NASH). NASH is a disease characterized by fat accumulation and inflammation in the liver, which may progress to liver fibrosis, cirrhosis and even liver cancer. Ilafibratenol helps improve liver function and slow down disease progression by regulating lipid metabolism and anti-inflammatory effects, so it is suitable for patients with metabolic syndrome and NASH.

The second suitable group of people are those NASH patients with type 2 diabetes. 2Patients with type 2 diabetes often suffer from fatty liver and insulin resistance, making the condition complex and difficult to treat. Ilafibratenol can activate PPARα and PPARδ, improve insulin sensitivity and lipid metabolism, help control blood sugar levels and reduce liver inflammatory response, thus having potential therapeutic value for patients with diabetes combined with NASH.

In addition, irafibratenol is suitable for patients with early-stage liver fibrosis, especially those with mild to moderate fibrosis in their liver tissue but who have not yet developed advanced cirrhosis. By regulating inflammation and fibrosis pathways, irafibratenol is expected to delay the process of fibrosis, reduce liver damage, and improve quality of life. Such patients may obtain better prognosis if they receive irafibratenol during early intervention.

Finally, irafibratenol is also suitable for people who are at higher risk of liver disease due to obesity, abnormal lipid metabolism and chronic inflammation. These patients often have imbalances in fat metabolism and chronic low-grade inflammation, which can easily lead to liver damage in the long term. Ilafibratenol regulates fatty acid metabolism and anti-inflammatory response by activating the PPAR pathway, helping to restore the normal metabolic function of the liver, reducing the risk of disease, and playing a dual role in prevention and treatment.

Reference materials:https://www.drugs.com/donanemab.html